<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?npg-journal-abbreviation?><?properties open_access?><?DTDIdentifier.IdentifierValue -//NPGSJ//DTD full length article DTD version 7.0 XML//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ajarticle_v7_x.dtd?><?SourceDTD.Version 7.0?><?ConverterInfo.XSLTName naturesa2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id><journal-title-group><journal-title>Translational Psychiatry</journal-title></journal-title-group><issn pub-type="epub">2158-3188</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4471287</article-id><article-id pub-id-type="pii">tp201556</article-id><article-id pub-id-type="doi">10.1038/tp.2015.56</article-id><article-id pub-id-type="pmid">25966365</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A molecular model for neurodevelopmental disorders</article-title><alt-title alt-title-type="running">A model for neurodevelopmental disorders</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gigek</surname><given-names>C O</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="author-notes" rid="note1"><sup>2</sup></xref><xref ref-type="author-notes" rid="note2"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>E S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="author-notes" rid="note1"><sup>2</sup></xref><xref ref-type="author-notes" rid="note2"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ota</surname><given-names>V K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="author-notes" rid="note1"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maussion</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vaillancourt</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Diallo</surname><given-names>A B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lopez</surname><given-names>J P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Crapper</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vasuta</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>G G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ernst</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Psychiatry, McGill Group for Suicide Studies, McGill University</institution>, Montreal, QC, <country>Canada</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label><institution>Douglas Hospital Research Institute, 6875 LaSalle Boulevard</institution>, Frank Common Building Room 2101.2 Verdun, QC, <country>Canada</country> H4H 1R3. E-mail: <email>carl.ernst@mcgill.ca</email></corresp><fn fn-type="present-address" id="note1"><label>2</label><p>Current address: Disciplina de Gen&#x000e9;tica, Departamento de Morfologia e Gen&#x000e9;tica, Escola Paulista de Medicina/Universidade Federal de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP, Brazil.</p></fn><fn fn-type="present-address" id="note2"><label>3</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>05</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>12</day><month>05</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>5</month><year>2015</year></pub-date><volume>5</volume><issue>5</issue><fpage>e565</fpage><lpage/><history><date date-type="received"><day>11</day><month>03</month><year>2015</year></date><date date-type="accepted"><day>24</day><month>03</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Macmillan Publishers Limited</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Macmillan Publishers Limited</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><!--author-paid--><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><abstract><p>Genes implicated in neurodevelopmental disorders (NDDs) important in cognition and behavior may have convergent function and several cellular pathways have been implicated, including protein translational control, chromatin modification, and synapse assembly and maintenance. Here, we test the convergent effects of methyl-CpG binding domain 5 (<italic>MBD5)</italic> and special AT-rich binding protein 2 (<italic>SATB2)</italic> reduced dosage in human neural stem cells (NSCs), two genes implicated in 2q23.1 and 2q33.1 deletion syndromes, respectively, to develop a generalized model for NDDs. We used short hairpin RNA stably incorporated into healthy neural stem cells to supress <italic>MBD5</italic> and <italic>SATB2</italic> expression, and massively parallel RNA sequencing, DNA methylation sequencing and microRNA arrays to test the hypothesis that a primary etiology of NDDs is the disruption of the balance of NSC proliferation and differentiation. We show that reduced dosage of either gene leads to significant overlap of gene-expression patterns, microRNA patterns and DNA methylation states with control NSCs in a differentiating state, suggesting that a unifying feature of 2q23.1 and 2q33.1 deletion syndrome may be a lack of regulation between proliferation and differentiation in NSCs, as we observed previously for <italic>TCF4</italic> and <italic>EHMT1</italic> suppression following a similar experimental paradigm. We propose a model of NDDs whereby the balance of NSC proliferation and differentiation is affected, but where the molecules that drive this effect are largely specific to disease-causing genetic variation. NDDs are diverse, complex and unique, but the optimal balance of factors that determine when and where neural stem cells differentiate may be a major feature underlying the diverse phenotypic spectrum of NDDs.</p></abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Neurodevelopmental disorders (NDDs) that affect behavior and cognition are caused by a wide variety of mutations, and several hypotheses have been put forward to understand the underlying features of the disease. The identification of mutations in <italic>MECP2</italic><sup><xref ref-type="bibr" rid="bib1">1</xref></sup> and <italic>FMR1</italic><sup><xref ref-type="bibr" rid="bib2">2</xref></sup> in the 1990s suggested a role for chromatin modification and genomic regulation. The chromatin modification hypothesis<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> has continued to receive support, and mutations in other genes<sup><xref ref-type="bibr" rid="bib4">4</xref></sup> related to genomic regulation have been identified in several cases.<sup><xref ref-type="bibr" rid="bib5">5</xref></sup> Discoveries in 2003 and 2004 led to a different theory about the underlying biology of NDDs, specifically autistic disorders, based on the identification of mutations in <italic>NLGN3</italic> and <italic>NLGN4.</italic><sup><xref ref-type="bibr" rid="bib6">6</xref></sup> This paved the way for the synaptic hypothesis of NDDs,<sup><xref ref-type="bibr" rid="bib7">7</xref>, <xref ref-type="bibr" rid="bib8">8</xref></sup> which states that NDDs are caused by dysfunctional assembly or maintenance of synapses, a hypothesis which continues to be supported by the discovery of more mutations in non-NLGN genes involved in synapse formation or stability.<sup><xref ref-type="bibr" rid="bib9">9</xref>, <xref ref-type="bibr" rid="bib10">10</xref></sup> Protein translation has also been associated to NDDs,<sup><xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib12">12</xref></sup> and in conjunction with the chromatin modification hypothesis, suggests that regulation of major cell processes in neurons may predispose to NDDs. The degree to which these disparate hypotheses may be connected is not known, although there is evidence to support WNT signaling as a potential convergence point.<sup><xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib14">14</xref></sup></p><p>The purpose of the current work is to identify a convergence point of NDDs on the basis of the two genes studied here, and to propose a molecular model that might apply to neurodevelopmental disorders more generally. We selected two genes associated with neurodevelopment disorders to identify convergence points, largely due to previous gene discovery studies<sup><xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib15">15</xref></sup> in which we participated. <italic>Methyl-CpG binding domain</italic> (<italic>MBD</italic>) <italic>5</italic> is a member of the MBD family characterized by a 70 amino-acid region thought to mediate association with methylated residues. <italic>MBD5</italic> protein contains a PWWP (pro-trp-trp-pro) domain, thought to be important in cell division, growth and differentiation.<sup><xref ref-type="bibr" rid="bib16">16</xref>, <xref ref-type="bibr" rid="bib17">17</xref></sup> Mutations in <italic>MBD5</italic> are thought to be important in the clinical phenotype of 2q23.1 deletion syndrome,<sup><xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib19">19</xref></sup> where subjects with a deletion in this region of chromosome 2 show intellectual disability and autistic-like features. Other studies also support the association of mutations in <italic>MBD5</italic> and autism spectrum disorders (ASD),<sup><xref ref-type="bibr" rid="bib15">15</xref>, <xref ref-type="bibr" rid="bib20">20</xref></sup> though there is a large heterogeneity in phenotype. <italic>Special AT-rich binding protein 2</italic> (<italic>SATB2</italic>) is a transcription factor that associates with AT-rich regions of the genome and the nuclear matrix,<sup><xref ref-type="bibr" rid="bib21">21</xref>, <xref ref-type="bibr" rid="bib22">22</xref></sup> and is thought to be involved in chromatin modification in neurons.<sup><xref ref-type="bibr" rid="bib23">23</xref></sup><italic>SATB2</italic> is found on 2q33.1 and reduced dosage of <italic>SATB2</italic> is thought to be a major cause of 2q33.1 deletion syndrome,<sup><xref ref-type="bibr" rid="bib24">24</xref></sup> characterized by cleft palate,<sup><xref ref-type="bibr" rid="bib25">25</xref></sup> severe speech delay, intellectual disability and behavioral problems, including ASD.<sup><xref ref-type="bibr" rid="bib24">24</xref>, <xref ref-type="bibr" rid="bib26">26</xref></sup></p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>This work was reviewed and approved by the ethical review board of the Douglas Hospital Research Institute of McGill University.</p><sec><title>Cell culture</title><p>Fetal brain cells (FBCs) are ReNcells derived form the ventral mesencephalon of human fetal brain (Millipore SCC008). Cells were grown on poly-L-ornithine/laminin (Sigma, St. Louis, MO, USA; P3655-50MG and l2020) coated six-well plates. Cells were maintained in 70&#x00025; DMEM, 2&#x00025; B27, 1&#x00025; Pen/Strep (Life Technologies, Foster City, CA, USA) 30&#x00025; Ham's F12 (Mediatech, Herndon, VA, USA) and 20&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup> bFGF (R&#x00026;D Systems, Minneapolis, MN, USA, 233-FB-025), 20 ng&#x02009;ml<sup>&#x02212;1</sup> EGF (Sigma E9644) and 5&#x02009;&#x003bc;g&#x02009;ml<sup>&#x02212;1</sup> heparin (Sigma). Differentiation is triggered by removing growth factors from media and letting cells grow for 30 days, with media changes every 3 days; proliferating cells are those maintained in bFGF and EGF.</p></sec><sec><title>Generation of stable knockdown cell lines</title><p>Short-hairpin RNAs (shRNAs) used in this study were designed, cloned into the pLKO.1 vector and packaged into lentivirus at the Broad Institute (Cambridge, MA, USA). To create stable cell lines, we transfected cells with lentivirus, then selected for cells where genomic integration occurred. For lentiviral transfection, FBCs were maintained at 30&#x00025; confluency (~400&#x02009;000 cells per well) in a six-well plate, then 20&#x02009;&#x003bc;l viral media in 2&#x02009;ml cell culture media without penicillin and streptomycin was added. Puromycin (Sigma; P8833; 0.8&#x02009;&#x003bc;l&#x02009;ml<sup>&#x02212;1</sup>), resistance to which is produced by the pLKO.1 vector, was added to cultures 48&#x02009;h after infection and this followed an initial media change 24&#x02009;h after transfection. Stable cell lines were selected by continuous maintenance of low-dose puromycin in culture media (0.2&#x02009;&#x003bc;l&#x02009;ml<sup>&#x02212;1</sup>). For controls, we used shRNAs targeting <italic>LacZ, GFP, RFP</italic> and <italic>Luc</italic> messenger RNA (mRNA). We refer to these controls as non-target (NT) controls because they were generated following identical procedures to <italic>MBD5</italic> and <italic>SATB2</italic> knockdown (KD) lines, but target mRNA was not present in the human genome.</p></sec><sec><title>RNAseq</title><p>RNAseq libraries were prepared from high quality (RIN&#x0003e;9; Agilent 2100 Bioanalyzer; Agilent Technologies, Santa Clara, CA, USA) RNA, where RNA was extracted with the Qiagen (Hilden, Germany) RNeasy kit following manufacturer's instructions for RNA isolation from cells. For bioinformatic processing, we first used FASTX-Toolkit (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://hannonlab.cshl.edu/fastx_toolkit/">http://hannonlab.cshl.edu/fastx_toolkit/</ext-link>) for adapter trimming. We used an average read quality &#x0003e;30 for the total read and retained only those reads whose length ranged from 30&#x02009;bp to 85&#x02009;bp, and removed all the duplicate reads. Alignment to the human genome was done with TopHat<sup><xref ref-type="bibr" rid="bib27">27</xref></sup> and Bowtie2.<sup><xref ref-type="bibr" rid="bib28">28</xref></sup> We allowed two mismatches, an insert size of 300&#x02009;000, a standard deviation of 100 and an expected (mean) inner distance between mate pairs of 150. We used Cufflinks2 (ref. <xref ref-type="bibr" rid="bib29">29</xref>) with default parameters to assemble aligned RNA-Seq reads into transcripts, to estimate their abundances, and to test differential expression. Gene ontology (GO) analyses were done under default conditions using DAVID.</p></sec><sec><title>Quantitative PCR</title><p>Reverse transcriptions were done on total RNA fraction to obtain complementary DNA in 40&#x02009;&#x003bc;l volume containing 1&#x02009;&#x003bc;g of total RNA; we used 0.5&#x02009;&#x003bc;g random hexamer primers, 0.5&#x02009;m<sc>M</sc> dNTPs, 0.01&#x02009;M DTT and 400&#x02009;U M-MLV RT (Carlsbad, CA, USA). For gene quantification, we ordered pre-designed Taqman primers, where each well included 6&#x02009;&#x003bc;l of 2X gene-expression mastermix, 0.6&#x02009;&#x003bc;l of 20X primer mix, 3.4&#x02009;&#x003bc;l of RNase free water and 2&#x02009;&#x003bc;l of complementary DNA. &#x003b2;-Actin and GAPDH were used as internal controls for normalization. We used the ABI 7900 light cycler for all the experiments and manufacturer's software for processing and analysis.</p></sec><sec><title>MicroRNA analysis</title><p>MicroRNAs were processed using the nCounter Human miRNA expression kit (NanoString Technologies, Seattle, WA, USA) at the NanoString facility at the Jewish General hospital, and all samples were run in duplicate. The nCounter data were processed using NanoStringNorm in R, with all data normalized to the geometric mean and microRNA spike-in controls, according to manufacturer's instructions. All the data were analyzed in R. For microRNA quantitative PCR (qPCR), the microRNA reverse transcription kit (Applied Biosystems, Burlington, ON, Canada) and specific primers to endogenous control and mir targets (&#x00023;001093: RNU6B; Applied Biosystems) were used to generate complementary DNA from the same microRNA extracted for the NanoString analysis. For each reaction, the PCR mix included 10&#x02009;&#x003bc;l of 2X NoAmperaseUNG mastermix (Applied Biosystems), 1&#x02009;&#x003bc;l of primers/probe mix and 2&#x02009;&#x003bc;l of complementary DNA, H<sub>2</sub>0 20&#x02009;&#x003bc;l.</p></sec><sec><title>Reduced representation bisulfite sequencing</title><p>We followed BisQC, a multiplexed bisulfite sequencing pipeline that we developed<sup><xref ref-type="bibr" rid="bib30">30</xref>, <xref ref-type="bibr" rid="bib31">31</xref></sup> for reduced representation bisulfite sequencing library preparation stages. We used TrimGalore followed by Bismark<sup><xref ref-type="bibr" rid="bib32">32</xref></sup> to align bisulfite-treated reads to a reference genome with Bowtie 2 (with zero mismatches allowed in a seed alignment during multi-seed alignment). We also used BisSNP, a package based on the Genome Analysis Toolkit map-reduce framework for genotyping and accurate DNA methylation calling in bisulfite-treated massively parallel sequencing with the Illumina directional library protocol, to identify those methylated regions that may be confounded by genetic variation&#x02014;these positions were removed from all the analyses. Only CpG sites with coverage &#x0003e;5X were included, and we excluded the 0.1&#x00025; of CpGs that showed the highest coverage for each sample. We defined CpG clusters as any contiuous set of CpG sites within 50&#x02009;bp of another CpG site, and used methylation frequency at each CpG site within a cluster in <italic>MBD5</italic> KD or <italic>SATB2</italic> KD compared with NT controls as values in <italic>a t</italic>-test.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Generation of NSC models of reduced dosage associated with neurodevelopmental disorders</title><p>To model genomic dosage disorders, we used KD technology in a human FBC line derived from a healthy fetus, where this cell line has been thoroughly characterized.<sup><xref ref-type="bibr" rid="bib33">33</xref></sup> We used multiple shRNA vectors targeting different regions of either <italic>MBD5</italic> or <italic>SATB2</italic> mRNA packaged into lentivirus and infected FBCs with either of these constructs or any of four NT control constructs. After KD of either gene followed by puromycin selection, we extracted RNA from each cell and performed qPCR using primers targeting <italic>MBD5</italic> or <italic>SATB2</italic> mRNA. For MBD5 KD, we found that two of four constructs show significant decrease in expression of <italic>MBD5</italic> (<xref ref-type="fig" rid="fig1">Figure 1a</xref>) of 64&#x00025; and 99&#x00025; (s.d.=25&#x00025;). For SATB2, we found that all the three shRNA constructs were able to knock down <italic>SATB2</italic> (<xref ref-type="fig" rid="fig1">Figure 1b</xref>) at levels ranging from 31, 61 and 70&#x00025; knockdown (s.d.=21&#x00025;). We selected two shRNAs per gene for western blot validation and confirmed decreased expression at the protein level (<xref ref-type="fig" rid="fig1">Figures 1c and d</xref>), with knockdown levels of MBD5 protein down 65 and 61&#x00025; (s.d.=3&#x00025;), and for SATB2 protein was down 31 and 54&#x00025; (s.d.=16&#x00025;). We also performed immunocytochemistry to ensure that proliferating FBCs express both genes in all cells, as expected. We observed nuclear localization of SATB2 and cytoplasmic localization of MBD5 in all neural stem cells (NSCs; <xref ref-type="fig" rid="fig1">Figure 1e</xref>). We proposed that MBD5 might function as a methylated RNA binding molecule in the cytoplasm, where methylated RNA may be important in stem cell proliferation.<sup><xref ref-type="bibr" rid="bib34">34</xref></sup></p></sec><sec><title>Reduced dosage of MBD5 or SATB2 leads to mRNA expression patterns more characteristic of differentiating than proliferating neural stem cells</title><p>Our previous work investigating reduced dosage of <italic>TCF4</italic> and <italic>EHMT1</italic> suggested that modeling genomic dosage disorders in NSCs made them more characteristic of a differentiating cell state compared with their actual proliferating state, implying a convergence point for at least some neurodevelopmental disorders.<sup><xref ref-type="bibr" rid="bib33">33</xref></sup> To test this hypothesis in the <italic>MBD5</italic> KD and <italic>SATB2</italic> KD models, we performed RNAseq using two shRNA constructs per gene and four non-target control shRNA, then generated a list of differentially expressed genes for each reduced dosage model compared with control shRNA. For <italic>MBD5</italic> KD decreased expression genes, we found an overrepresentation of genes implicated in cell division and proliferation (<xref ref-type="fig" rid="fig1">Figure 1f</xref>&#x02014;MBD5), whereas for increased expression genes, there was an overrepresentation of genes involved in neural differentiation. For <italic>SATB2</italic> KD decreased expression genes, we observed an overrepresentation of genes implicated in apoptosis or cell death (<xref ref-type="fig" rid="fig1">Figure 1f</xref>&#x02014;SATB2), whereas increased expression genes were implicated in neurodevelopment. These data suggest that reduced dosage of either <italic>MBD5</italic> or <italic>SATB2</italic> leads to increased expression of genes related to neural differentiation, consistent with previous results from reduced dosage models of <italic>TCF4</italic> and <italic>EHMT1</italic>. With respect to repression of cell proliferation markers, we find that only <italic>MBD5</italic> KD had repressed markers associated with cell proliferation, likely consistent with the function of the PWWP domain, and suggesting that genes implicated in NDDs can affect NSC differentiation, affect NSC proliferation or do both.</p><p>Before empirically testing whether <italic>MBD5</italic> KD or <italic>SATB2</italic> KD were in a state more characteristic of differentiating cells, we grew NT control cells and differentiated them for 30 days in the absence of growth factors. We extracted RNA and performed RNAseq on these differentiating cells, and compared them with the same NT control cells in the proliferating state. We then performed GO analyses for all genes that showed differential expression in this experiment and found, as expected, GO terms related to the cell cycle for decreased expression genes and GO terms related to neurodevelopment for increased expression genes (<xref ref-type="fig" rid="fig1">Figure 1f</xref>&#x02014;cell state). This sets a baseline for what is expected with respect to &#x02018;proliferating' genes and &#x02018;differentiating' genes in control conditions.</p><p>If RNA expression differences detected in the <italic>MBD5</italic> KD and <italic>SATB2</italic> KD experiments are characteristic of differentiating NT control cells, than the same genes that show differential expression in the reduced dosage models should show differential expression in the cell state experiment. To test this hypothesis, we intersected all genes that were significantly differentially expressed across each analysis and computed the probability of the intersection occurring by chance (<xref ref-type="fig" rid="fig1">Figure 1g</xref>), using the hypergeometric probability.<sup><xref ref-type="bibr" rid="bib35">35</xref></sup> First, we calculated the total number of tests by determining the maximum number of mRNA that could be identified in these RNAseq experiments. We found that 12&#x02009;640&#x02013;14&#x02009;901 different mRNA could be detected (FPKM &#x0003e;1) across different experiments, and we use these numbers as our global pool of mRNA. For genes that showed significantly decreased expression in <italic>MBD5</italic> KD, we found that 90.3&#x00025; were also significantly decreased in differentiating NSCs, whereas 56.1&#x00025; of genes that showed increased expression in <italic>MBD5</italic> KD were common with those in the cell state experiment, and this overlap is strongly unlikely to occur by chance (<xref ref-type="fig" rid="fig1">Figure 1g</xref>). For mRNA from <italic>SATB2</italic> KD that showed decreased expression, we found that 36.8&#x00025; were also significantly differentially expressed in the cell state experiment (<xref ref-type="fig" rid="fig1">Figure 1g</xref>), whereas, for <italic>SATB2</italic> KD mRNA that showed increased expression, 28.9&#x00025; were common to cell state. For both <italic>MBD5</italic> KD and <italic>SATB2</italic> KD, we found a strong correlation between differentially expressed genes and expression differences specific to differentiating cells (<xref ref-type="fig" rid="fig1">Figures 1h and i</xref>, <italic>P</italic>&#x0003c;0.01).</p><p>We next asked what the probability was for the same genes that were significantly differentially expressed in both <italic>MBD5</italic> KD and <italic>SATB2</italic> KD cells to determine the degree of convergence between these two disease models. We found that eight genes were common to both analyses (<xref ref-type="fig" rid="fig1">Figure 1g</xref>), an event unlikely to occur by chance (hyper <italic>P</italic>=3.3X10<sup>&#x02212;</sup><sup>6</sup>), all of which were directionally identical between cell models. Differentially expressed genes common to both reduced dosage models that were increased were <italic>NCAN,</italic><sup><xref ref-type="bibr" rid="bib36">36</xref></sup><italic>GPR56,</italic><sup><xref ref-type="bibr" rid="bib37">37</xref></sup><italic>TTYH1</italic><sup><xref ref-type="bibr" rid="bib38">38</xref></sup> and <italic>PLP1,</italic><sup><xref ref-type="bibr" rid="bib39">39</xref></sup> all of which are implicated in cell differentiation. Genes that were downregulated in both cell models included <italic>MSMO1, FDFT1, SERPINE1</italic> and <italic>ANXA2</italic>, where <italic>MSMO1</italic> and <italic>FDFT1</italic> are involved in cholesterol biosynthesis. We selected three genes known to be involved in neural differentiation and <italic>ANXA2,</italic> which is reported to have a role in psychiatric disorders<sup><xref ref-type="bibr" rid="bib40">40</xref></sup> and neuritogenesis<sup><xref ref-type="bibr" rid="bib41">41</xref></sup> for RNAseq validation (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S1</xref>).</p><p>Because of the effect in <italic>MBD5</italic> KD of decreased expression of genes associated with the cell cycle, we performed both cell proliferation and cell cycle assays (<xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> and <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S2</xref>). We found no deficits of cell proliferation or cell cycle progression in <italic>MBD5</italic> KD cells compared with non-target controls (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S2</xref>). We also performed targeted qPCR analysis of two genes implicated in neural differentiation (<italic>HES6</italic> and <italic>MALAT1</italic>) and two genes implicated in cell proliferation (<italic>CDK1</italic> and <italic>CKS2</italic>; <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S2</xref>). All RNAseq data were confirmed, strongly supporting our conclusion from the GO analysis.</p></sec><sec><title>Reduced dosage of MBD5 or SATB2 leads to microRNA expression patterns more characteristic of differentiating than proliferating cells</title><p>We wanted to further pursue our hypothesis by looking at other measurable cell features and following the similar experimental paradigm to RNAseq experiments. To this end, we performed genome-wide microRNA experiments in <italic>MBD</italic>5 KD, <italic>SATB2</italic> KD, proliferating non-target controls and differentiating non-target controls.</p><p>We performed global microRNA analysis using four non-target controls and the two <italic>MBD5</italic> KD cell lines, all of which was performed in replicate. We excluded any microRNA not expressed in either 6/7 controls or in 3/4 MBD5 KD, which left 254 microRNAs for analysis. We found 21 differentially expressed microRNA (<italic>P</italic>&#x0003c;0.05), though none passed FDR correction (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). For differentiating and proliferating non-target controls cells, we extracted microRNA in both states (<italic>n</italic>=4 samples per cell state, in duplicate) and performed global NanoString analysis. There were 395 microRNAs that were detectable, and many microRNAs that showed significant differences between cell states (259 microRNAs with <italic>P</italic>-values &#x0003c;0.05). To test whether the same microRNAs that were differentially expressed in <italic>MBD5</italic> KD were also differentially expressed in the cell state experiment, we plotted data from the cell state experiment for only those microRNAs that were also differentially expressed in the <italic>MBD5</italic> KD experiment (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). Strikingly, we found that all microRNA changes were directionally identical: there were four microRNAs with increased expression in the <italic>MBD5</italic> KD experiment and these were identical to the cell state experiment. These four microRNAs, (mir99,<sup><xref ref-type="bibr" rid="bib42">42</xref></sup> mir9,<sup><xref ref-type="bibr" rid="bib43">43</xref></sup> mir30b<sup><xref ref-type="bibr" rid="bib44">44</xref></sup> and mir92a-3p<sup><xref ref-type="bibr" rid="bib45">45</xref></sup>) are associated with differentiation or suppression of proliferation, further supporting our hypothesis. The relationship between <italic>MBD5</italic> KD and differentiating cells is reflected in Pearson correlation coefficient of the log2 fold-change differences between <italic>MBD5</italic> KD and non-target differentiating cells (Pearson <italic>R</italic>=0.66, <italic>P</italic>=0.0011). Immediately apparent is that the magnitude of the expression differences are much more pronounced in NT differentiating cells than in <italic>MBD5</italic> KD cells (compare heights of the bars in <xref ref-type="fig" rid="fig2">Figures 2a and b</xref>). To confirm the validity of the NanoString results, we performed targeted microRNA qPCR on two targets (<xref ref-type="fig" rid="fig2">Figure 2c</xref>: miR-99-5p, <italic>P</italic>=3.96 &#x000d7; 10<sup>&#x02212;5</sup>; <xref ref-type="fig" rid="fig2">Figure 2d</xref>: mir-9-5p, <italic>P</italic>=6.23X10<sup>&#x02212;9</sup>).</p><p>For <italic>SATB2</italic> KD, we identified 31 microRNAs with nominal <italic>P</italic>-values &#x0003c;0.05 with mir-let7e, mir-221-3p and mir-93-5p showing FDR significant <italic>q</italic>-values &#x0003c;0.10. Comparing the microRNAs identified as differentially expressed in the <italic>SATB2</italic> KD experiment (<xref ref-type="fig" rid="fig2">Figure 2e</xref>) to those same microRNAs present in the cell state experiment (<xref ref-type="fig" rid="fig2">Figure 2f</xref>) revealed a significant correlation (Pearson correlation of log2 fold-change differences=0.59, <italic>P</italic>=0.01, where the direction of change was identical for each microRNA), with a more extreme extent of change in the cell state experiment, similar to findings to <italic>MBD5</italic> KD. We performed qPCR on two microRNAs from this analysis (<xref ref-type="fig" rid="fig2">Figures 2g and h</xref>: miR-let-7e; <italic>P</italic>=0.11; miR-9-5p; <italic>P</italic>=0.11). For comparison, we provide the expression changes of all significantly differentially expressed microRNA in the cell state experiment (<xref ref-type="fig" rid="fig2">Figure 2i</xref>), where 106/259 microRNAs showed increased expression in differentiating cells.</p></sec><sec><title>Reduced dosage of MBD5 or SATB2 leads to DNA methylation patterns more characteristic of differentiating than proliferating cells</title><p>To determine whether DNA methylation patterns in <italic>MBD5</italic> KD or <italic>SATB2</italic> KD have taken on characteristics of differentiating cells, we performed whole-genome methylation experiments in reduced genomic space. First, we compared <italic>MBD5</italic> KD (two shRNA and two replicates each) to non-target control proliferating cells (four shRNAs) and found 390 genome-wide significant CpG clusters (<xref ref-type="fig" rid="fig3">Figure 3a</xref>), where a cluster is defined as two or more CpGs that are &#x0003c;50&#x02009;bp apart. For <italic>SATB2</italic> KD (two shRNAs and two replicates each), we found 697 genome-wide significant CpG clusters; whereas, in the non-target cell state experiment, we found 2877 genome-wide significant CpG clusters. We calculated the hypergeometric probability for both reduced dosage models with cell state and we found that overlapping CpG clusters were significantly unlikely to occur by chance (<xref ref-type="fig" rid="fig3">Figures 3b and c</xref>), suggesting that these particular clusters may be important in cell differentiation and/or proliferation. To test whether <italic>MBD5</italic> and <italic>SATB2</italic> reduced dosage model methylation regions converged, we intersected data from each analysis and calculated the hypergeometric probability of the overlap, which was highly significant (<xref ref-type="fig" rid="fig3">Figure 3d</xref>). To support the idea that differential methylation is relevant to NSC proliferation or differentiation, we mapped all differentially methylated clusters to genes (within 5Kb 5' and 2Kb 3' <xref ref-type="fig" rid="fig3">Figures 3g and i</xref>), then performed GO analysis with these gene lists. Across each GO analysis, we found terms related to neurodevelopment to be overrepresented (<xref ref-type="fig" rid="fig3">Figures 3e and g</xref>).</p><p>We calculated the Pearson correlation for all CpG clusters that were significant in both a reduced-dosage model and in the cell state experiment. For <italic>MBD5</italic> KD, there were 102 clusters that met this criteria and we found a Pearson correlation of 0.49 when comparing <italic>MBD5</italic> KD to the mean methylation frequency in proliferating control cells, and a Pearson value of 0.76 when the same MBD5 KD methylation frequencies were correlated with mean per cluster methylation frequencies in NT differentiating cells, implying that the methylation in <italic>MBD5</italic> KD is more similar to differentiating NSCs than to proliferating NSCs. For <italic>SATB2</italic> KD, we found Pearson values of 0.51 and 0.53, where the higher Pearson value was with differentiating cells, though these two values are essentially identical.</p><p>We observed a much stronger Pearson value between each KD line than with either KD line with NT cells (<italic>MBD5</italic> KD and <italic>SATB2</italic> KD: Pearson=0.87; <italic>MBD5</italic> KD and NT pro: 0.37; <italic>SATB2</italic> KD and NT pro: 0.29). This Pearson correlation between <italic>SATB2</italic> KD and <italic>MBD5</italic> KD suggests that the directionality of methylation frequency between KD lines is similar for those clusters that are significantly different from proliferating non-target control cells. We show methylation frequency data for the top 10 most significant CpG clusters for each reduced expression analysis (<xref ref-type="fig" rid="fig3">Figures 3h and j</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>We tested the hypothesis that reduced dosage of two different genes made neural stem cells more characteristic of differentiating cells than their actual proliferating state, an idea that is well supported by many other genes associated with NDDs (<xref rid="tbl1" ref-type="table">Table 1</xref>). We suggest that both protein translation and chromatin modification hypotheses of NDDs important in behavior and cognition converge on this pathway, an idea in line with the WNT hypothesis of ASDs.<sup><xref ref-type="bibr" rid="bib14">14</xref></sup> Specifically, we suggest that it is not chromatin modification or protein translation <italic>per se</italic>, but rather the functional effects of genes in these categories that impact neural differentiation. Our data suggest that there is significant molecular overlap between NDDs caused by different genetic variation, but that this is not overwhelming (5&#x02013;15&#x00025; across cell features)&#x02014;it appears that outcome of these different genetic variation (regulation of NSC differentiation and/or proliferation) is the crucial factor, and that many different molecules drive this effect. A mutation in any element of this pathway could lead to an NDD, with the degree of overlap across different genetic variation dependent on how close two genes are in the regulation of cell proliferation or differentiation. We suggest that aberrant neural differentiation may lead to inappropriate neural connections, which may explain why so many different synaptic-associated genes are also observed in ASD cases<sup><xref ref-type="bibr" rid="bib46">46</xref></sup> (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>We provide several lines of supporting evidence that reduced dosage of two different genes leads neural stem cells to adopt features more characteristic of differentiating than proliferating neural stem cells. We show that mRNAs, microRNAs and DNA methylation clusters that are significantly different in <italic>SATB2</italic> KD or <italic>MBD5</italic> KD compared with non-target controls, significantly overlap with the same features that are significantly different when we compare control proliferating NSCs to differentiating NSCs. This leads us to suggest that reduced dosage of either <italic>MBD5</italic> or <italic>SATB2</italic> causes neural stem cells to be more characteristic of differentiating cells than proliferating cells, and that this may be a unifying feature of neurodevelopmental disorders more generally. Together with our previous work investigating <italic>EHMT1</italic> and <italic>TCF4</italic> suppression,<sup><xref ref-type="bibr" rid="bib33">33</xref></sup> two other repressive factors thought to regulate the expression of many genes, we suggest that all four molecules act as a brake to repress a cell differentiation program (that is, maintain a proliferative state) in NSCs functioning to ensure the proper timing of neural differentiation. Independent suppression of all four factors in NSCs leads cells to take on characteristics of differentiating cells, though all four NSC models appear to continue to proliferate normally. When we looked at the function of several genes and loci associated with NDDs, we find that they all affect the balance of proliferation and differentiation in neural stem cells (<xref rid="tbl1" ref-type="table">Table 1</xref>). This suggests that the current data may not be specific to <italic>MBD5</italic> and <italic>SATB2</italic> reduced dosage, but may apply to many NDDs; thus we propose the current model (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><sec><title>Predictions of the model</title><sec><title>Repression or enhancement of NSC proliferation or differentiation underlie ASDs/NDDs</title><p>All genes (<italic>TCF4</italic>, <italic>EHMT1,</italic><sup><xref ref-type="bibr" rid="bib33">33</xref></sup>
<italic>SATB2</italic> and <italic>MBD5</italic>) that we have studied to develop the current model appear to enhance NSC differentiation, suggesting that NSCs may be primed to differentiate too early; however, a &#x02018;positive control' example of an NDD, Fragile X syndrome caused by a trinucleotide repeat expansion and leading to supressed expression of <italic>FMR1</italic>, shows deficits in differentiation in iPSC-neural stem cell models,<sup><xref ref-type="bibr" rid="bib73">73</xref></sup> possibly suggesting Fragile X syndrome is caused by increased proliferation markers and decreased differentiation markers. In other words, <italic>FMR1</italic>'s role might be to propel NSC differentiation. Similarly, iPSC models of Rett's Syndrome, caused by mutations in <italic>MECP2</italic>, suggest an impaired neuronal maturation phenotype.<sup><xref ref-type="bibr" rid="bib74">74</xref></sup> Together, this implies no &#x02018;directionality' but rather an altered balance of proliferation or differentiation in NSCs as the underlying feature in NDDs.</p></sec><sec><title>CNVs implicated in NDDs will show reciprocal effects on NSC differentiation and proliferation (16p11.2 and 1q21.1 as examples)</title><p>The structural variants at 16p11.2 are among the most common genetic causes of NDDs and ASDs<sup><xref ref-type="bibr" rid="bib71">71</xref></sup> and occur either as a genomic deletion or duplication affecting ~26 genes. Clinical spectrum of the 16p11.2 deletions includes ASDs, language impairment, intellectual disability increased brain volume and body mass index.<sup><xref ref-type="bibr" rid="bib75">75</xref></sup> The 16p11.2 duplication is associated with a less severe and more variable phenotype including ASDs, intellectual disability and a decrease in brain volume.<sup><xref ref-type="bibr" rid="bib71">71</xref></sup> The 1q21.1 deletion or duplication occur in ~0.7&#x00025; of all ID/ASD cases.<sup><xref ref-type="bibr" rid="bib72">72</xref></sup> The copy number variant (CNV, copy gain or loss) is 1.35&#x02009;Mb encompassing seven genes, where deletion cases have mild-to-moderate developmental delay, and ~65&#x00025; show microcephaly.<sup><xref ref-type="bibr" rid="bib72">72</xref></sup> Duplication cases also show mild-to-moderate developmental delay, and macrocephaly has been detected in &#x0003e;60&#x00025; of duplication cases.<sup><xref ref-type="bibr" rid="bib76">76</xref></sup></p><p>CNVs at 1q21.1 and 16p11.2 may be implicated in neural stem cell proliferation and differentiation. For 16p11.2, a recent paper found that, &#x02018;microcephaly is caused by decreased proliferation of neuronal progenitors with concomitant increase in apoptosis in the developing brain, whereas macrocephaly arises by increased proliferation and no changes in apoptosis'.<sup><xref ref-type="bibr" rid="bib77">77</xref></sup> This is direct evidence for our model, though one which has not been assessed in human cells. Evidence from a mouse model of 16p11.2 deletion in mouse also supports these findings&#x02014;a recent study showed enhanced differentiation and supressed proliferation of neural stem cells.<sup><xref ref-type="bibr" rid="bib78">78</xref></sup> Further, <italic>ERK1</italic> (aka <italic>MAPK3</italic>) is one of the 26 genes in the 16p11.2 region, and there are many studies documenting its role in neural differentiation and proliferation.<sup><xref ref-type="bibr" rid="bib79">79</xref></sup> For 1q21.1 syndrome, <italic>CHD1L</italic> is one of seven genes in the CNV regions, and is capable of inducing spontaneous tumors in tissue where it is injected in mice<sup><xref ref-type="bibr" rid="bib80">80</xref></sup>&#x02014;strongly suggesting a functional role in cell proliferation. Similarly, <italic>BCL9</italic>, a gene important in apoptosis and also one of seven genes in the 1q21.1 region, has a well-known role in cell proliferation in tumors.<sup><xref ref-type="bibr" rid="bib81">81</xref></sup> The model of NDD proposed here predicts that human NSC models of either 16p11.2 or 1q21.1 CNVs will have reciprocal effects (for example, increased differentiation markers for the deletion and decreased differentiation markers for the duplication).</p></sec><sec><title>Cell membrane proteins associated with ASDs/NDDs have a function in NSC proliferation and differentiation</title><p>Several genes associated with neurodevelopmental disorders include genes coding for channels (for example, <italic>GRIN2B</italic>, <italic>SCN2A</italic>) and synaptic adhesion proteins such as <italic>NRXN1</italic> or <italic>NLGN4X</italic>. All of the genes that we have tested to date (<italic>TCF4</italic>, <italic>EHMT1,</italic><sup><xref ref-type="bibr" rid="bib33">33</xref></sup>
<italic>SATB2</italic> and <italic>MBD5</italic>) are thought to act as transcriptional repressors either through direct interaction with DNA or indirectly through protein complex intermediaries, and lead to increased NSC differentiation when gene dosage is suppressed. One might suggest that this model might be restricted to repressor molecules that directly interact with the genome; however, we suggest that genes that code for channels or cell adhesion molecules may also be important in maintaining the balance of cell proliferation and differentiation in neural stem cells. We propose that altered electrical balance and cell&#x02013;cell or cell&#x02013;matrix contacts may also be important to determining when and where NSCs differentiate, and that this is the primary cause of NDDs. Our model predicts, controversially, that synaptic adhesion may be an important feature of NSC proliferation/differentiation and that altered synaptic connectivity is a secondary effect of altered NSC differentiation, rather than a primary cause of NDDs important to behavior.</p><p>The mechanistic property of proteins most associated with ASD is that of synapse assembly, maintenance or connectivity, including such genes as <italic>NLGN4, NRXN1, SHANK1/3, SYNGAP1</italic> and many others. We propose that deficits in regulating the proper timing of neural differentiation may lead to inappropriate connections between neurons (<xref ref-type="fig" rid="fig4">Figure 4</xref>). NSCs must balance several external signaling cues (attractant or repellent cues, for example) and intrinsic ones (such as birth date) before making a commitment to differentiate. Slight changes to this program may lead to subtle connectivity problems in the brain, which may be expressed later in life as a social communication disorder.</p></sec></sec><sec><title>Open questions</title><p>The development of this model is based on the genes studied here, our previous work,<sup><xref ref-type="bibr" rid="bib33">33</xref></sup> and functional studies of genes implicated in ASD/NDDs with a role in behavior (<xref rid="tbl1" ref-type="table">Table 1</xref>). Several questions remain to fully understand the relevance of this model. (1) Are deficits in NSC proliferation and differentiation the primary deficit causing NDDs or a secondary defect? This is testable using assays developed here for studies using iPSC models of disease&#x02014;a practice that is occurring for almost all genetically defined NDDs. (2) What cell type should be used to study these deficits and are the effects cell autonomous? Modeling NDDs in stem cells is in its infancy and several concerns remain about derivation, differentiation and characterization. It is not immediately clear how these models recapitulate human brain development nor is it clear what cell type should be used (or what, precisely, defines a cell type). Experiments in culture also suffer from an inability to assess context, meaning that NSCs <italic>in vivo</italic> may behave very differently than cells in a dish. Further, effects observed in one cell type may not be recapitulated in a different cell type, even from the same donor. (3) How does the model apply to NDDs associated with metabolic disorders?</p></sec></sec></body><back><ack><p>This work was funded by a grant from the Scottish Rite Charitable Foundation of Canada to CE, who receives salary support from the Canada Research Chairs program. COG was supported by a CNPQ (Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico) scholarship, ESC and VKO were supported by a fellowship from FAPESP (Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado de S&#x000e3;o Paulo), KV and JPL are supported by the Canadian Institute of Health Research, and LC is supported by the Fonds de Recherche de Quebec Sante.</p></ack><fn-group><fn><p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)</p></fn></fn-group><notes><p>The authors declare no conflicts of interest.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amir</surname><given-names>RE</given-names></name><name><surname>Van den Veyver</surname><given-names>IB</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>CQ</given-names></name><name><surname>Francke</surname><given-names>U</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group><article-title>Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2</article-title><source>Nat Genet</source><year>1999</year><volume>23</volume><fpage>185</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">10508514</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinds</surname><given-names>HL</given-names></name><name><surname>Ashley</surname><given-names>CT</given-names></name><name><surname>Sutcliffe</surname><given-names>JS</given-names></name><name><surname>Nelson</surname><given-names>DL</given-names></name><name><surname>Warren</surname><given-names>ST</given-names></name><name><surname>Housman</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome</article-title><source>Nat Genet</source><year>1993</year><volume>3</volume><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">8490651</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schanen</surname><given-names>NC</given-names></name></person-group><article-title>Epigenetics of autism spectrum disorders</article-title><source>Hum Mol Genet</source><year>2006</year><volume>15</volume>Spec No 2<fpage>R138</fpage><lpage>R150</lpage><pub-id pub-id-type="pmid">16987877</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernier</surname><given-names>R</given-names></name><name><surname>Golzio</surname><given-names>C</given-names></name><name><surname>Xiong</surname><given-names>B</given-names></name><name><surname>Stessman</surname><given-names>HA</given-names></name><name><surname>Coe</surname><given-names>BP</given-names></name><name><surname>Penn</surname><given-names>O</given-names></name><etal/></person-group><article-title>Disruptive CHD8 mutations define a subtype of autism early in development</article-title><source>Cell</source><year>2014</year><volume>158</volume><fpage>263</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">24998929</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talkowski</surname><given-names>ME</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Blumenthal</surname><given-names>I</given-names></name><name><surname>Pillalamarri</surname><given-names>V</given-names></name><name><surname>Chiang</surname><given-names>C</given-names></name><name><surname>Heilbut</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>525</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">22521361</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamain</surname><given-names>S</given-names></name><name><surname>Quach</surname><given-names>H</given-names></name><name><surname>Betancur</surname><given-names>C</given-names></name><name><surname>Rastam</surname><given-names>M</given-names></name><name><surname>Colineaux</surname><given-names>C</given-names></name><name><surname>Gillberg</surname><given-names>IC</given-names></name><etal/></person-group><article-title>Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism</article-title><source>Nat Genet</source><year>2003</year><volume>34</volume><fpage>27</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">12669065</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cline</surname><given-names>H</given-names></name></person-group><article-title>Synaptogenesis: a balancing act between excitation and inhibition</article-title><source>Curr Biol</source><year>2005</year><volume>15</volume><fpage>R203</fpage><lpage>R205</lpage><pub-id pub-id-type="pmid">15797012</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebrahimi-Fakhari</surname><given-names>D</given-names></name><name><surname>Sahin</surname><given-names>M</given-names></name></person-group><article-title>Autism and the synapse: emerging mechanisms and mechanism-based therapies</article-title><source>Curr Opin Neurol</source><year>2015</year><volume>28</volume><fpage>91</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">25695134</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durand</surname><given-names>CM</given-names></name><name><surname>Betancur</surname><given-names>C</given-names></name><name><surname>Boeckers</surname><given-names>TM</given-names></name><name><surname>Bockmann</surname><given-names>J</given-names></name><name><surname>Chaste</surname><given-names>P</given-names></name><name><surname>Fauchereau</surname><given-names>F</given-names></name><etal/></person-group><article-title>Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>25</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">17173049</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bena</surname><given-names>F</given-names></name><name><surname>Bruno</surname><given-names>DL</given-names></name><name><surname>Eriksson</surname><given-names>M</given-names></name><name><surname>van Ravenswaaij-Arts</surname><given-names>C</given-names></name><name><surname>Stark</surname><given-names>Z</given-names></name><name><surname>Dijkhuizen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Molecular and clinical characterization of 25 individuals with exonic deletions of NRXN1 and comprehensive review of the literature</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2013</year><volume>162B</volume><fpage>388</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">23533028</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gkogkas</surname><given-names>CG</given-names></name><name><surname>Khoutorsky</surname><given-names>A</given-names></name><name><surname>Ran</surname><given-names>I</given-names></name><name><surname>Rampakakis</surname><given-names>E</given-names></name><name><surname>Nevarko</surname><given-names>T</given-names></name><name><surname>Weatherill</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Autism-related deficits via dysregulated eIF4E-dependent translational control</article-title><source>Nature</source><year>2013</year><volume>493</volume><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">23172145</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelleher</surname><given-names>RJ</given-names><suffix>3rd</suffix></name><name><surname>Bear</surname><given-names>MF</given-names></name></person-group><article-title>The autistic neuron: troubled translation</article-title><source>Cell</source><year>2008</year><volume>135</volume><fpage>401</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">18984149</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalkman</surname><given-names>HO</given-names></name></person-group><article-title>A review of the evidence for the canonical Wnt pathway in autism spectrum disorders</article-title><source>Mol Autism</source><year>2012</year><volume>3</volume><fpage>10</fpage><pub-id pub-id-type="pmid">23083465</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krumm</surname><given-names>N</given-names></name><name><surname>O'Roak</surname><given-names>BJ</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name></person-group><article-title>A de novo convergence of autism genetics and molecular neuroscience</article-title><source>Trends Neurosci</source><year>2014</year><volume>37</volume><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">24387789</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talkowski</surname><given-names>ME</given-names></name><name><surname>Mullegama</surname><given-names>SV</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>van Bon</surname><given-names>BW</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Repnikova</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder</article-title><source>Am J Hum Genet</source><year>2011</year><volume>89</volume><fpage>551</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">21981781</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Lam</surname><given-names>R</given-names></name><name><surname>Tempel</surname><given-names>W</given-names></name><name><surname>Amaya</surname><given-names>MF</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Structural and histone binding ability characterizations of human PWWP domains</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e18919</fpage><pub-id pub-id-type="pmid">21720545</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stec</surname><given-names>I</given-names></name><name><surname>Nagl</surname><given-names>SB</given-names></name><name><surname>van Ommen</surname><given-names>GJ</given-names></name><name><surname>den Dunnen</surname><given-names>JT</given-names></name></person-group><article-title>The PWWP domain: a potential protein-protein interaction domain in nuclear proteins influencing differentiation</article-title><source>FEBS Lett</source><year>2000</year><volume>473</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10802047</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Bon</surname><given-names>BW</given-names></name><name><surname>Koolen</surname><given-names>DA</given-names></name><name><surname>Brueton</surname><given-names>L</given-names></name><name><surname>McMullan</surname><given-names>D</given-names></name><name><surname>Lichtenbelt</surname><given-names>KD</given-names></name><name><surname>Ades</surname><given-names>LC</given-names></name><etal/></person-group><article-title>The 2q23.1 microdeletion syndrome: clinical and behavioural phenotype</article-title><source>Eur J Hum Genet</source><year>2010</year><volume>18</volume><fpage>163</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">19809484</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaillard</surname><given-names>S</given-names></name><name><surname>Dubourg</surname><given-names>C</given-names></name><name><surname>Gerard-Blanluet</surname><given-names>M</given-names></name><name><surname>Delahaye</surname><given-names>A</given-names></name><name><surname>Pasquier</surname><given-names>L</given-names></name><name><surname>Dupont</surname><given-names>C</given-names></name><etal/></person-group><article-title>2q23.1 microdeletion identified by array comparative genomic hybridisation: an emerging phenotype with Angelman-like features</article-title><source>J Med Genet</source><year>2009</year><volume>46</volume><fpage>847</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">18812405</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>SR</given-names></name><name><surname>Mullegama</surname><given-names>SV</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Dagli</surname><given-names>AI</given-names></name><name><surname>Hatchwell</surname><given-names>E</given-names></name><name><surname>Allen</surname><given-names>WP</given-names></name><etal/></person-group><article-title>Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures</article-title><source>Eur J Hum Genet</source><year>2010</year><volume>18</volume><fpage>436</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">19904302</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britanova</surname><given-names>O</given-names></name><name><surname>Akopov</surname><given-names>S</given-names></name><name><surname>Lukyanov</surname><given-names>S</given-names></name><name><surname>Gruss</surname><given-names>P</given-names></name><name><surname>Tarabykin</surname><given-names>V</given-names></name></person-group><article-title>Novel transcription factor Satb2 interacts with matrix attachment region DNA elements in a tissue-specific manner and demonstrates cell-type-dependent expression in the developing mouse CNS</article-title><source>Eur J Neurosci</source><year>2005</year><volume>21</volume><fpage>658</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">15733084</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcamo</surname><given-names>EA</given-names></name><name><surname>Chirivella</surname><given-names>L</given-names></name><name><surname>Dautzenberg</surname><given-names>M</given-names></name><name><surname>Dobreva</surname><given-names>G</given-names></name><name><surname>Farinas</surname><given-names>I</given-names></name><name><surname>Grosschedl</surname><given-names>R</given-names></name><etal/></person-group><article-title>Satb2 regulates callosal projection neuron identity in the developing cerebral cortex</article-title><source>Neuron</source><year>2008</year><volume>57</volume><fpage>364</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">18255030</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gyorgy</surname><given-names>AB</given-names></name><name><surname>Szemes</surname><given-names>M</given-names></name><name><surname>de Juan Romero</surname><given-names>C</given-names></name><name><surname>Tarabykin</surname><given-names>V</given-names></name><name><surname>Agoston</surname><given-names>DV</given-names></name></person-group><article-title>SATB2 interacts with chromatin-remodeling molecules in differentiating cortical neurons</article-title><source>Eur J Neurosci</source><year>2008</year><volume>27</volume><fpage>865</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">18333962</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Ballif</surname><given-names>BC</given-names></name><name><surname>Lucas</surname><given-names>A</given-names></name><name><surname>Spence</surname><given-names>EJ</given-names></name><name><surname>Powell</surname><given-names>C</given-names></name><name><surname>Aylsworth</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Small deletions of SATB2 cause some of the clinical features of the 2q33.1 microdeletion syndrome</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e6568</fpage><pub-id pub-id-type="pmid">19668335</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>FitzPatrick</surname><given-names>DR</given-names></name><name><surname>Carr</surname><given-names>IM</given-names></name><name><surname>McLaren</surname><given-names>L</given-names></name><name><surname>Leek</surname><given-names>JP</given-names></name><name><surname>Wightman</surname><given-names>P</given-names></name><name><surname>Williamson</surname><given-names>K</given-names></name><etal/></person-group><article-title>Identification of SATB2 as the cleft palate gene on 2q32-q33</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><fpage>2491</fpage><lpage>2501</lpage><pub-id pub-id-type="pmid">12915443</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usui</surname><given-names>D</given-names></name><name><surname>Shimada</surname><given-names>S</given-names></name><name><surname>Shimojima</surname><given-names>K</given-names></name><name><surname>Sugawara</surname><given-names>M</given-names></name><name><surname>Kawasaki</surname><given-names>H</given-names></name><name><surname>Shigematu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Interstitial duplication of 2q32.1-q33.3 in a patient with epilepsy, developmental delay, and autistic behavior</article-title><source>Am J Med Genet A</source><year>2013</year><volume>161A</volume><fpage>1078</fpage><lpage>1084</lpage><pub-id pub-id-type="pmid">23463730</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>TopHat: discovering splice junctions with RNA-Seq</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">19289445</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pop</surname><given-names>M</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>Ultrafast and memory-efficient alignment of short DNA sequences to the human genome</article-title><source>Genome Biol</source><year>2009</year><volume>10</volume><fpage>R25</fpage><pub-id pub-id-type="pmid">19261174</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Goff</surname><given-names>L</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kelley</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks</article-title><source>Nat Protoc</source><year>2012</year><volume>7</volume><fpage>562</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">22383036</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>GG</given-names></name><name><surname>Diallo</surname><given-names>AB</given-names></name><name><surname>Poujol</surname><given-names>R</given-names></name><name><surname>Nagy</surname><given-names>C</given-names></name><name><surname>Staffa</surname><given-names>A</given-names></name><name><surname>Vaillancourt</surname><given-names>K</given-names></name><etal/></person-group><article-title>BisQC: an operational pipeline for multiplexed bisulfite sequencing</article-title><source>BMC Genomics</source><year>2014</year><volume>15</volume><fpage>290</fpage><pub-id pub-id-type="pmid">24734894</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>C</given-names></name><name><surname>McGowan</surname><given-names>PO</given-names></name><name><surname>Deleva</surname><given-names>V</given-names></name><name><surname>Meaney</surname><given-names>MJ</given-names></name><name><surname>Szyf</surname><given-names>M</given-names></name><name><surname>Turecki</surname><given-names>G</given-names></name></person-group><article-title>The effects of pH on DNA methylation state: <italic>in vitro</italic> and post-mortem brain studies</article-title><source>J Neurosci Methods</source><year>2008</year><volume>174</volume><fpage>123</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">18656499</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>F</given-names></name><name><surname>Andrews</surname><given-names>SR</given-names></name></person-group><article-title>Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications</article-title><source>Bioinformatics</source><year>2011</year><volume>27</volume><fpage>1571</fpage><lpage>1572</lpage><pub-id pub-id-type="pmid">21493656</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>ES</given-names></name><name><surname>Gigek</surname><given-names>CO</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Diallo</surname><given-names>AB</given-names></name><name><surname>Maussion</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>GG</given-names></name><etal/></person-group><article-title>Molecular convergence of neurodevelopmental disorders</article-title><source>Am J Hum Genet</source><year>2014</year><volume>95</volume><fpage>490</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">25307298</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geula</surname><given-names>S</given-names></name><name><surname>Moshitch-Moshkovitz</surname><given-names>S</given-names></name><name><surname>Dominissini</surname><given-names>D</given-names></name><name><surname>Mansour</surname><given-names>AA</given-names></name><name><surname>Kol</surname><given-names>N</given-names></name><name><surname>Salmon-Divon</surname><given-names>M</given-names></name><etal/></person-group><article-title>Stem cells. m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation</article-title><source>Science</source><year>2015</year><volume>347</volume><fpage>1002</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">25569111</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fury</surname><given-names>W</given-names></name><name><surname>Batliwalla</surname><given-names>F</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>Overlapping probabilities of top ranking gene lists, hypergeometric distribution, and stringency of gene selection criterion</article-title><source>Conf Proc IEEE Eng Med Biol Soc</source><year>2006</year><volume>1</volume><fpage>5531</fpage><lpage>5534</lpage><pub-id pub-id-type="pmid">17947148</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedlander</surname><given-names>DR</given-names></name><name><surname>Milev</surname><given-names>P</given-names></name><name><surname>Karthikeyan</surname><given-names>L</given-names></name><name><surname>Margolis</surname><given-names>RK</given-names></name><name><surname>Margolis</surname><given-names>RU</given-names></name><name><surname>Grumet</surname><given-names>M</given-names></name></person-group><article-title>The neuronal chondroitin sulfate proteoglycan neurocan binds to the neural cell adhesion molecules Ng-CAM/L1/NILE and N-CAM, and inhibits neuronal adhesion and neurite outgrowth</article-title><source>J Cell Biol</source><year>1994</year><volume>125</volume><fpage>669</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">7513709</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>BI</given-names></name><name><surname>Tietjen</surname><given-names>I</given-names></name><name><surname>Atabay</surname><given-names>KD</given-names></name><name><surname>Evrony</surname><given-names>GD</given-names></name><name><surname>Johnson</surname><given-names>MB</given-names></name><name><surname>Asare</surname><given-names>E</given-names></name><etal/></person-group><article-title>Evolutionarily dynamic alternative splicing of GPR56 regulates regional cerebral cortical patterning</article-title><source>Science</source><year>2014</year><volume>343</volume><fpage>764</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">24531968</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefaniuk</surname><given-names>M</given-names></name><name><surname>Swiech</surname><given-names>L</given-names></name><name><surname>Dzwonek</surname><given-names>J</given-names></name><name><surname>Lukasiuk</surname><given-names>K</given-names></name></person-group><article-title>Expression of Ttyh1, a member of the Tweety family in neurons <italic>in vitro</italic> and <italic>in vivo</italic> and its potential role in brain pathology</article-title><source>J Neurochem</source><year>2010</year><volume>115</volume><fpage>1183</fpage><lpage>1194</lpage><pub-id pub-id-type="pmid">20874767</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiihara</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Moriyama</surname><given-names>K</given-names></name><name><surname>Uematsu</surname><given-names>M</given-names></name><name><surname>Sameshima</surname><given-names>K</given-names></name></person-group><article-title>A novel PLP1 frameshift mutation causing a milder form of Pelizaeus-Merzbacher disease</article-title><source>Brain Dev</source><year>2014</year><volume>37</volume><fpage>455</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">25043250</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>DM</given-names></name><name><surname>Kalkhof</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Ihling</surname><given-names>C</given-names></name><name><surname>Stingl</surname><given-names>C</given-names></name><name><surname>Mechtler</surname><given-names>K</given-names></name><etal/></person-group><article-title>Annexin A2/P11 interaction: new insights into annexin A2 tetramer structure by chemical crosslinking, high-resolution mass spectrometry, and computational modeling</article-title><source>Proteins</source><year>2007</year><volume>69</volume><fpage>254</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">17607745</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacovina</surname><given-names>AT</given-names></name><name><surname>Zhong</surname><given-names>F</given-names></name><name><surname>Khazanova</surname><given-names>E</given-names></name><name><surname>Lev</surname><given-names>E</given-names></name><name><surname>Deora</surname><given-names>AB</given-names></name><name><surname>Hajjar</surname><given-names>KA</given-names></name></person-group><article-title>Neuritogenesis and the nerve growth factor-induced differentiation of PC-12 cells requires annexin II-mediated plasmin generation</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>49350</fpage><lpage>49358</lpage><pub-id pub-id-type="pmid">11679580</pub-id></mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Malhotra</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Matecic</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>C</given-names></name><etal/></person-group><article-title>miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><fpage>1313</fpage><lpage>1324</lpage><pub-id pub-id-type="pmid">21212412</pub-id></mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Victor</surname><given-names>MB</given-names></name><name><surname>Richner</surname><given-names>M</given-names></name><name><surname>Hermanstyne</surname><given-names>TO</given-names></name><name><surname>Ransdell</surname><given-names>JL</given-names></name><name><surname>Sobieski</surname><given-names>C</given-names></name><name><surname>Deng</surname><given-names>PY</given-names></name><etal/></person-group><article-title>Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts</article-title><source>Neuron</source><year>2014</year><volume>84</volume><fpage>311</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">25374357</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>WT</given-names></name><name><surname>Ye</surname><given-names>YP</given-names></name><name><surname>Zhang</surname><given-names>NJ</given-names></name><name><surname>Li</surname><given-names>TT</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Cui</surname><given-names>YM</given-names></name><etal/></person-group><article-title>MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2</article-title><source>J Pathol</source><year>2014</year><volume>232</volume><fpage>415</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">24293274</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharifi</surname><given-names>M</given-names></name><name><surname>Salehi</surname><given-names>R</given-names></name><name><surname>Gheisari</surname><given-names>Y</given-names></name><name><surname>Kazemi</surname><given-names>M</given-names></name></person-group><article-title>Inhibition of microRNA miR-92a induces apoptosis and inhibits cell proliferation in human acute promyelocytic leukemia through modulation of p63 expression</article-title><source>Mol Biol Rep</source><year>2014</year><volume>41</volume><fpage>2799</fpage><lpage>2808</lpage><pub-id pub-id-type="pmid">24481878</pub-id></mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudhof</surname><given-names>TC</given-names></name></person-group><article-title>Neuroligins and neurexins link synaptic function to cognitive disease</article-title><source>Nature</source><year>2008</year><volume>455</volume><fpage>903</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">18923512</pub-id></mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>KC</given-names></name><name><surname>Han</surname><given-names>SM</given-names></name><name><surname>Go</surname><given-names>HS</given-names></name><name><surname>Seo</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Translational regulation of NeuroD1 expression by FMRP: involvement in glutamatergic neuronal differentiation of cultured rat primary neural progenitor cells</article-title><source>Cell Mol Neurobiol</source><year>2014</year><volume>34</volume><fpage>297</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">24338128</pub-id></mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>MicroRNA-130b targets Fmr1 and regulates embryonic neural progenitor cell proliferation and differentiation</article-title><source>Biochem Biophys Res Commun</source><year>2013</year><volume>439</volume><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">24021279</pub-id></mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scotto-Lomassese</surname><given-names>S</given-names></name><name><surname>Nissant</surname><given-names>A</given-names></name><name><surname>Mota</surname><given-names>T</given-names></name><name><surname>Neant-Fery</surname><given-names>M</given-names></name><name><surname>Oostra</surname><given-names>BA</given-names></name><name><surname>Greer</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Fragile X mental retardation protein regulates new neuron differentiation in the adult olfactory bulb</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>2205</fpage><lpage>2215</lpage><pub-id pub-id-type="pmid">21307257</pub-id></mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callan</surname><given-names>MA</given-names></name><name><surname>Cabernard</surname><given-names>C</given-names></name><name><surname>Heck</surname><given-names>J</given-names></name><name><surname>Luois</surname><given-names>S</given-names></name><name><surname>Doe</surname><given-names>CQ</given-names></name><name><surname>Zarnescu</surname><given-names>DC</given-names></name></person-group><article-title>Fragile X protein controls neural stem cell proliferation in the Drosophila brain</article-title><source>Hum Mol Genet</source><year>2010</year><volume>19</volume><fpage>3068</fpage><lpage>3079</lpage><pub-id pub-id-type="pmid">20504994</pub-id></mixed-citation></ref><ref id="bib51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castren</surname><given-names>M</given-names></name><name><surname>Tervonen</surname><given-names>T</given-names></name><name><surname>Karkkainen</surname><given-names>V</given-names></name><name><surname>Heinonen</surname><given-names>S</given-names></name><name><surname>Castren</surname><given-names>E</given-names></name><name><surname>Larsson</surname><given-names>K</given-names></name><etal/></person-group><article-title>Altered differentiation of neural stem cells in fragile X syndrome</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>17834</fpage><lpage>17839</lpage><pub-id pub-id-type="pmid">16314562</pub-id></mixed-citation></ref><ref id="bib52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Chau</surname><given-names>KF</given-names></name><name><surname>Santistevan</surname><given-names>NJ</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cell cycle-linked MeCP2 phosphorylation modulates adult neurogenesis involving the Notch signalling pathway</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>5601</fpage><pub-id pub-id-type="pmid">25420914</pub-id></mixed-citation></ref><ref id="bib53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magri</surname><given-names>L</given-names></name><name><surname>Cambiaghi</surname><given-names>M</given-names></name><name><surname>Cominelli</surname><given-names>M</given-names></name><name><surname>Alfaro-Cervello</surname><given-names>C</given-names></name><name><surname>Cursi</surname><given-names>M</given-names></name><name><surname>Pala</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions</article-title><source>Cell Stem Cell</source><year>2011</year><volume>9</volume><fpage>447</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">22056141</pub-id></mixed-citation></ref><ref id="bib54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandel</surname><given-names>S</given-names></name><name><surname>Spivak-Pohis</surname><given-names>I</given-names></name><name><surname>Gozes</surname><given-names>I</given-names></name></person-group><article-title>ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance</article-title><source>J Mol Neurosci</source><year>2008</year><volume>35</volume><fpage>127</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">18286385</pub-id></mixed-citation></ref><ref id="bib55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>M</given-names></name><name><surname>Guerri</surname><given-names>C</given-names></name></person-group><article-title>The peptide NAP promotes neuronal growth and differentiation through extracellular signal-regulated protein kinase and Akt pathways, and protects neurons co-cultured with astrocytes damaged by ethanol</article-title><source>J Neurochem</source><year>2007</year><volume>103</volume><fpage>557</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">17623041</pub-id></mixed-citation></ref><ref id="bib56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawaguchi</surname><given-names>D</given-names></name><name><surname>Yoshimatsu</surname><given-names>T</given-names></name><name><surname>Hozumi</surname><given-names>K</given-names></name><name><surname>Gotoh</surname><given-names>Y</given-names></name></person-group><article-title>Selection of differentiating cells by different levels of delta-like 1 among neural precursor cells in the developing mouse telencephalon</article-title><source>Development</source><year>2008</year><volume>135</volume><fpage>3849</fpage><lpage>3858</lpage><pub-id pub-id-type="pmid">18997111</pub-id></mixed-citation></ref><ref id="bib57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chenn</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>CA</given-names></name></person-group><article-title>Regulation of cerebral cortical size by control of cell cycle exit in neural precursors</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>365</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">12130776</pub-id></mixed-citation></ref><ref id="bib58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuoc</surname><given-names>TC</given-names></name><name><surname>Boretius</surname><given-names>S</given-names></name><name><surname>Sansom</surname><given-names>SN</given-names></name><name><surname>Pitulescu</surname><given-names>ME</given-names></name><name><surname>Frahm</surname><given-names>J</given-names></name><name><surname>Livesey</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Chromatin regulation by BAF170 controls cerebral cortical size and thickness</article-title><source>Dev Cell</source><year>2013</year><volume>25</volume><fpage>256</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">23643363</pub-id></mixed-citation></ref><ref id="bib59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez-Gomez</surname><given-names>HR</given-names></name><name><surname>Vergano-Vera</surname><given-names>E</given-names></name><name><surname>Abad</surname><given-names>JL</given-names></name><name><surname>Bulfone</surname><given-names>A</given-names></name><name><surname>Moratalla</surname><given-names>R</given-names></name><name><surname>de Pablo</surname><given-names>F</given-names></name><etal/></person-group><article-title>The T-box brain 1 (Tbr1) transcription factor inhibits astrocyte formation in the olfactory bulb and regulates neural stem cell fate</article-title><source>Mol Cell Neurosci</source><year>2011</year><volume>46</volume><fpage>108</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">20807572</pub-id></mixed-citation></ref><ref id="bib60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valli</surname><given-names>E</given-names></name><name><surname>Trazzi</surname><given-names>S</given-names></name><name><surname>Fuchs</surname><given-names>C</given-names></name><name><surname>Erriquez</surname><given-names>D</given-names></name><name><surname>Bartesaghi</surname><given-names>R</given-names></name><name><surname>Perini</surname><given-names>G</given-names></name><etal/></person-group><article-title>CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells</article-title><source>Biochim Biophys Acta</source><year>2012</year><volume>1819</volume><fpage>1173</fpage><lpage>1185</lpage><pub-id pub-id-type="pmid">22921766</pub-id></mixed-citation></ref><ref id="bib61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Chow</surname><given-names>LM</given-names></name><name><surname>Bayazitov</surname><given-names>IT</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Gilbertson</surname><given-names>RJ</given-names></name><name><surname>Zakharenko</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Pten deletion causes mTorc1-dependent ectopic neuroblast differentiation without causing uniform migration defects</article-title><source>Development</source><year>2012</year><volume>139</volume><fpage>3422</fpage><lpage>3431</lpage><pub-id pub-id-type="pmid">22874917</pub-id></mixed-citation></ref><ref id="bib62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiyama</surname><given-names>M</given-names></name><name><surname>Skoultchi</surname><given-names>AI</given-names></name><name><surname>Nakayama</surname><given-names>KI</given-names></name></person-group><article-title>Histone H1 recruitment by CHD8 is essential for suppression of the Wnt-beta-catenin signaling pathway</article-title><source>Mol Cell Biol</source><year>2012</year><volume>32</volume><fpage>501</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">22083958</pub-id></mixed-citation></ref><ref id="bib63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-Alcantar</surname><given-names>A</given-names></name><name><surname>Gonzalez-Sandoval</surname><given-names>A</given-names></name><name><surname>Escalante-Alcalde</surname><given-names>D</given-names></name><name><surname>Lomeli</surname><given-names>H</given-names></name></person-group><article-title>Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle</article-title><source>Cell Tissue Res</source><year>2011</year><volume>345</volume><fpage>137</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">21647563</pub-id></mixed-citation></ref><ref id="bib64"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Fukai</surname><given-names>R</given-names></name><name><surname>Hiraki</surname><given-names>Y</given-names></name><name><surname>Yofune</surname><given-names>H</given-names></name><name><surname>Tsurusaki</surname><given-names>Y</given-names></name><name><surname>Nakashima</surname><given-names>M</given-names></name><name><surname>Saitsu</surname><given-names>H</given-names></name><etal/></person-group><article-title>A case of autism spectrum disorder arising from a de novo missense mutation in POGZ</article-title><source>J Hum Genet</source><year>2015</year>doi: <pub-id pub-id-type="doi">10.1038/jhg.2015.13</pub-id>e-pub ahead of print 19 February 2015.</mixed-citation></ref><ref id="bib65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nozawa</surname><given-names>RS</given-names></name><name><surname>Nagao</surname><given-names>K</given-names></name><name><surname>Masuda</surname><given-names>HT</given-names></name><name><surname>Iwasaki</surname><given-names>O</given-names></name><name><surname>Hirota</surname><given-names>T</given-names></name><name><surname>Nozaki</surname><given-names>N</given-names></name><etal/></person-group><article-title>Human POGZ modulates dissociation of HP1alpha from mitotic chromosome arms through Aurora B activation</article-title><source>Nat Cell Biol</source><year>2010</year><volume>12</volume><fpage>719</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">20562864</pub-id></mixed-citation></ref><ref id="bib66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicetto</surname><given-names>D</given-names></name><name><surname>Hahn</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>J</given-names></name><name><surname>Schneider</surname><given-names>TD</given-names></name><name><surname>Straub</surname><given-names>T</given-names></name><name><surname>David</surname><given-names>R</given-names></name><etal/></person-group><article-title>Suv4-20 h histone methyltransferases promote neuroectodermal differentiation by silencing the pluripotency-associated Oct-25 gene</article-title><source>PLoS Genet</source><year>2013</year><volume>9</volume><fpage>e1003188</fpage><pub-id pub-id-type="pmid">23382689</pub-id></mixed-citation></ref><ref id="bib67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Smibert</surname><given-names>CA</given-names></name><name><surname>Kaplan</surname><given-names>DR</given-names></name><name><surname>Miller</surname><given-names>FD</given-names></name></person-group><article-title>An eIF4E1/4E-T complex determines the genesis of neurons from precursors by translationally repressing a proneurogenic transcription program</article-title><source>Neuron</source><year>2014</year><volume>84</volume><fpage>723</fpage><lpage>739</lpage><pub-id pub-id-type="pmid">25456498</pub-id></mixed-citation></ref><ref id="bib68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuetz</surname><given-names>G</given-names></name><name><surname>Rosario</surname><given-names>M</given-names></name><name><surname>Grimm</surname><given-names>J</given-names></name><name><surname>Boeckers</surname><given-names>TM</given-names></name><name><surname>Gundelfinger</surname><given-names>ED</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name></person-group><article-title>The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells</article-title><source>J Cell Biol</source><year>2004</year><volume>167</volume><fpage>945</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">15569713</pub-id></mixed-citation></ref><ref id="bib69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Yamamoto</surname><given-names>V</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name></person-group><article-title>Functional impacts of NRXN1 knockdown on neurodevelopment in stem cell models</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e59685</fpage><pub-id pub-id-type="pmid">23536886</pub-id></mixed-citation></ref><ref id="bib70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Coba</surname><given-names>MP</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name></person-group><article-title>The functional genetic link of NLGN4X knockdown and neurodevelopment in neural stem cells</article-title><source>Hum Mol Genet</source><year>2013</year><volume>22</volume><fpage>3749</fpage><lpage>3760</lpage><pub-id pub-id-type="pmid">23710042</pub-id></mixed-citation></ref><ref id="bib71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>LA</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Korn</surname><given-names>JM</given-names></name><name><surname>Arking</surname><given-names>DE</given-names></name><name><surname>Miller</surname><given-names>DT</given-names></name><name><surname>Fossdal</surname><given-names>R</given-names></name><etal/></person-group><article-title>Association between microdeletion and microduplication at 16p11.2 and autism</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>667</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">18184952</pub-id></mixed-citation></ref><ref id="bib72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mefford</surname><given-names>HC</given-names></name><name><surname>Sharp</surname><given-names>AJ</given-names></name><name><surname>Baker</surname><given-names>C</given-names></name><name><surname>Itsara</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Buysse</surname><given-names>K</given-names></name><etal/></person-group><article-title>Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>1685</fpage><lpage>1699</lpage><pub-id pub-id-type="pmid">18784092</pub-id></mixed-citation></ref><ref id="bib73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheridan</surname><given-names>SD</given-names></name><name><surname>Theriault</surname><given-names>KM</given-names></name><name><surname>Reis</surname><given-names>SA</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Madison</surname><given-names>JM</given-names></name><name><surname>Daheron</surname><given-names>L</given-names></name><etal/></person-group><article-title>Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e26203</fpage><pub-id pub-id-type="pmid">22022567</pub-id></mixed-citation></ref><ref id="bib74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djuric</surname><given-names>U</given-names></name><name><surname>Cheung</surname><given-names>AY</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Mok</surname><given-names>RS</given-names></name><name><surname>Lai</surname><given-names>W</given-names></name><name><surname>Piekna</surname><given-names>A</given-names></name><etal/></person-group><article-title>MECP2e1 isoform mutation affects the form and function of neurons derived from Rett syndrome patient iPS cells</article-title><source>Neurobiol Dis</source><year>2015</year><volume>76C</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">25644311</pub-id></mixed-citation></ref><ref id="bib75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>E</given-names></name><name><surname>Nasir</surname><given-names>RH</given-names></name><name><surname>Fong</surname><given-names>A</given-names></name><name><surname>Lian</surname><given-names>A</given-names></name><name><surname>Hundley</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cognitive and behavioral characterization of 16p11.2 deletion syndrome</article-title><source>J Dev Behav Pediatr</source><year>2010</year><volume>31</volume><fpage>649</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">20613623</pub-id></mixed-citation></ref><ref id="bib76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolcetti</surname><given-names>A</given-names></name><name><surname>Silversides</surname><given-names>CK</given-names></name><name><surname>Marshall</surname><given-names>CR</given-names></name><name><surname>Lionel</surname><given-names>AC</given-names></name><name><surname>Stavropoulos</surname><given-names>DJ</given-names></name><name><surname>Scherer</surname><given-names>SW</given-names></name><etal/></person-group><article-title>1q21.1 Microduplication expression in adults</article-title><source>Genet Med</source><year>2013</year><volume>15</volume><fpage>282</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">23018752</pub-id></mixed-citation></ref><ref id="bib77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golzio</surname><given-names>C</given-names></name><name><surname>Willer</surname><given-names>J</given-names></name><name><surname>Talkowski</surname><given-names>ME</given-names></name><name><surname>Oh</surname><given-names>EC</given-names></name><name><surname>Taniguchi</surname><given-names>Y</given-names></name><name><surname>Jacquemont</surname><given-names>S</given-names></name><etal/></person-group><article-title>KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant</article-title><source>Nature</source><year>2012</year><volume>485</volume><fpage>363</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">22596160</pub-id></mixed-citation></ref><ref id="bib78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pucilowska</surname><given-names>J</given-names></name><name><surname>Vithayathil</surname><given-names>J</given-names></name><name><surname>Tavares</surname><given-names>EJ</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Karlo</surname><given-names>JC</given-names></name><name><surname>Landreth</surname><given-names>GE</given-names></name></person-group><article-title>The 16p11.2 Deletion Mouse Model of Autism Exhibits Altered Cortical Progenitor Proliferation and Brain Cytoarchitecture Linked to the ERK MAPK Pathway</article-title><source>J Neurosci</source><year>2015</year><volume>35</volume><fpage>3190</fpage><lpage>3200</lpage><pub-id pub-id-type="pmid">25698753</pub-id></mixed-citation></ref><ref id="bib79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Erk1/2 promotes proliferation and inhibits neuronal differentiation of neural stem cells</article-title><source>Neurosci Lett</source><year>2009</year><volume>461</volume><fpage>252</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">19539699</pub-id></mixed-citation></ref><ref id="bib80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>JD</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>BJ</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Tsang</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Transgenic CHD1L expression in mouse induces spontaneous tumors</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e6727</fpage><pub-id pub-id-type="pmid">19701453</pub-id></mixed-citation></ref><ref id="bib81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>M</given-names></name><name><surname>Carrasco</surname><given-names>DE</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Takada</surname><given-names>K</given-names></name><name><surname>Gatt</surname><given-names>ME</given-names></name><name><surname>Dutta-Simmons</surname><given-names>J</given-names></name><etal/></person-group><article-title>BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>7577</fpage><lpage>7586</lpage><pub-id pub-id-type="pmid">19738061</pub-id></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Information</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tp201556x1.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Generation of human neural stem cell (NSC) models of MBD5 and SATB2 suppression, and RNAseq comparative analysis. (<bold>a</bold>) <italic>MBD5</italic> gene-expression analysis in four cell lines that underwent <italic>MBD5</italic> shRNA lentiviral infection (blue bars). Numbers represent RNAi consortium (TRC) identifiers. Green bar represents mean <italic>MBD5</italic> expression across four independent non-target (NT) control cell lines. (<bold>b</bold>) <italic>SATB2</italic> gene-expression analysis in three independent cell lines (blue bar) and four independent non-target controls (green bar). (<bold>c</bold>) Western blot experiment showing the two <italic>MBD5</italic> KD cell lines with greatest degree of KD from <bold>a</bold> and one NT control, targeting LacZ mRNA. <italic>MBD5</italic> is detected at ~168 KDa. (<bold>d</bold>) Western blot analysis of <italic>SATB2</italic> knockdown in LacZ and two <italic>SATB2</italic> KD cell lines. (<bold>e</bold>) Immunocytochemical analysis of MBD5 and SATB2 protein demonstrating presence of both proteins in all cells, with a cytoplasmic distribution of MBD5 and nuclear localization of SATB2 protein. (<bold>f</bold>) Gene ontology analysis of differentially expressed mRNA in <italic>MBD5</italic> KD, <italic>SATB2</italic> KD and the cell state experiment (non-target proliferating cells compared with non-target differentiating cells). (<bold>g</bold>) Statistical analysis of the probability of observing overlapping significantly differentially expressed mRNA across each experiment. (<bold>h</bold>) mRNAs that overlap in <italic>MBD5</italic> KD proliferating cells and non-target differentiating cells are correlated. (<bold>i</bold>) mRNAs that overlap in <italic>SATB2</italic> KD proliferating cells and non-target differentiating cells are correlated. KD, knockdown; MBD, methyl-CpG binding domain; mRNA, messenger RNA; SATB, special AT-rich binding protein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tp201556f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>MicroRNA expression patterns in neural stem cell models of gene dosage disorders are more characteristic of differentiating non-target cells than proliferating non-target cells. (<bold>a</bold>) NanoString expression values for all microRNA with single point <italic>P</italic>-values &#x0003c;0.05 in the MBD5 KD experiment compared with non-target proliferating cells. (<bold>b</bold>) NanoString expression values for the same microRNAs identified in the MBD5 KD experiment but showing values for the cell state (differentiating non-target cells compared with proliferating non-target cells) experiment. (<bold>c</bold> and <bold>d</bold>) Quantitative PCR (qPCR) validation of two microRNAs identified in the MBD5 KD experiment. (<bold>e</bold>) NanoString expression values for all microRNA with single point <italic>P</italic>-values &#x0003c;0.05 in the SATB2 KD experiment (<bold>f</bold>) NanoString expression values for the same microRNAs identified in the SATB2 KD experiment, but showing values for the cell state (differentiating non-target cells compared with proliferating non-target cells) experiment. (<bold>g</bold> and <bold>h</bold>) qPCR validation of two microRNAs identified in the SATB2 KD experiment. (<bold>i</bold>) Distribution of microRNAs that are up- or downregulated in the cell state experiment plotted as a function of <italic>P</italic>-value. KD, knockdown; MBD, methyl-CpG binding domain; SATB, special AT-rich binding protein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tp201556f2"/></fig><fig id="fig3"><label>Figure 3</label><caption><p>DNA methylation patterns in neural stem cell models of gene dosage disorders are more characteristic of differentiating cells than proliferating cells. (<bold>a</bold>) Total number of CpG clusters detected and the total number of genome-wide significant CpG clusters that show differential methylation. (<bold>b</bold>) Graphical representation of the likelihood of observing overlapping CpG clusters in the MBD5 KD, (<bold>c</bold>) SATB2 KD and (<bold>d</bold>) cell state experiment. (<bold>e</bold>&#x02013;<bold>g</bold>) Significant GO terms associated with CpG clusters near genes for the cell state (<bold>e</bold>), MBD5 KD (<bold>f</bold>) and SATB2 KD (<bold>g</bold>) experiments. (<bold>h</bold>&#x02013;<bold>j</bold>) Traces showing methylation differences for the most significantly differentially methylated CpG clusters in (<bold>h</bold>) MBD5 KD, (<bold>i</bold>) SATB2 KD and (<bold>j</bold>) most significant CpG clusters that overlap in both SATB2 KD and MBD<italic>5</italic> KD. GO, gene ontology; KD, knockdown; MBD, methyl-CpG binding domain; SATB, special AT-rich binding protein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tp201556f3"/></fig><fig id="fig4"><label>Figure 4</label><caption><p>Molecular model for neurodevelopmental disorders. Genes with mutations associated with NDDs might affect specific cell processes such as protein translation or chromatin modification in such a way as to impact pathways important in NSC proliferation or differentiation, such as the WNT signaling pathway. The measureable outcome of different genetic variation associated with NDDs may be NSCs with altered regulation of the balance between NSC proliferation and differentiation. These vulnerabilities, specific to each mutation associated with NDDs, might affect the timing of neural stem cell differentiation causing neurons to connect inappropriately in a neural circuit or respond uncharacteristically to attractant or repellent cues. NDD, neurodevelopmental disorder; NSC, neural stem cell.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tp201556f4"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Examples of well-known genes and genetic loci implicated in ASDs and/or NDDs with reported effects on proliferation or differentiation in NSCs</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Gene</italic></th><th align="left" valign="top" charoff="50"><italic>Functional effect</italic></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>FMR1</italic></td><td align="left" valign="top" charoff="50">Regulation of cell differentiation<sup><xref ref-type="bibr" rid="bib47">47</xref>, <xref ref-type="bibr" rid="bib48">48</xref>, <xref ref-type="bibr" rid="bib49">49</xref>, <xref ref-type="bibr" rid="bib50">50</xref>, <xref ref-type="bibr" rid="bib51">51</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>MECP2</italic></td><td align="left" valign="top" charoff="50">Modulates the balance between proliferation and neural differentiation through the Notch signaling pathway<sup><xref ref-type="bibr" rid="bib52">52</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>TSC1/2</italic></td><td align="left" valign="top" charoff="50">Mutations cause premature differentiation and impaired maturation of neural precursor cells during both embryonic and postnatal development<sup><xref ref-type="bibr" rid="bib53">53</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>ADNP</italic></td><td align="left" valign="top" charoff="50">Role in neuronal differentiation and maintenance<sup><xref ref-type="bibr" rid="bib54">54</xref>, <xref ref-type="bibr" rid="bib55">55</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>DLL1</italic></td><td align="left" valign="top" charoff="50">Promotes neuronal differentiation in the telencephalon<sup><xref ref-type="bibr" rid="bib56">56</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>CTNNB1</italic></td><td align="left" valign="top" charoff="50">Functions in the decision of precursors to proliferate or differentiate during mammalian neuronal development<sup><xref ref-type="bibr" rid="bib57">57</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>SMARCC2</italic></td><td align="left" valign="top" charoff="50">Promotes indirect neurogenesis by increasing the pool of progenitors<sup><xref ref-type="bibr" rid="bib58">58</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>TBR1</italic></td><td align="left" valign="top" charoff="50">Promotes neuronal differentiation<sup><xref ref-type="bibr" rid="bib59">59</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>CDKL5</italic></td><td align="left" valign="top" charoff="50">Mutation blocks cell cycle and promotes differentiation in neurons<sup><xref ref-type="bibr" rid="bib60">60</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>PTEN</italic></td><td align="left" valign="top" charoff="50">Deletion causes neuroblast differentiation through mTORC1<sup><xref ref-type="bibr" rid="bib61">61</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>CHD8</italic></td><td align="left" valign="top" charoff="50">Negative regulator of the Wnt-&#x003b2;-catenin signaling pathway<sup><xref ref-type="bibr" rid="bib62">62</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>ARID1B</italic></td><td align="left" valign="top" charoff="50">Part of the SWI/SNF complex, a cell cycle control complex<sup><xref ref-type="bibr" rid="bib63">63</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>POGZ</italic></td><td align="left" valign="top" charoff="50">Regulation of mitosis and proliferation in neurons<sup><xref ref-type="bibr" rid="bib64">64</xref>, <xref ref-type="bibr" rid="bib65">65</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>SUV420H1</italic></td><td align="left" valign="top" charoff="50">Promotes neuroectodermal differentiation<sup><xref ref-type="bibr" rid="bib66">66</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>EIF4E</italic></td><td align="left" valign="top" charoff="50">Suppresses a pro-neurogenic program in neural progenitor cells<sup><xref ref-type="bibr" rid="bib67">67</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>SHANK3</italic></td><td align="left" valign="top" charoff="50">Mediates sustained MAPK and PI3K signaling<sup><xref ref-type="bibr" rid="bib68">68</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>NRXN1</italic></td><td align="left" valign="top" charoff="50">Reduced expression alters neuron differentiation<sup><xref ref-type="bibr" rid="bib69">69</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50"><italic>NLGN4X</italic></td><td align="left" valign="top" charoff="50">Reduced expression delays neurodevelopment<sup><xref ref-type="bibr" rid="bib70">70</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">16p11.2 CNV</td><td align="left" valign="top" charoff="50">Reciprocal deletion and duplication CNV implicated in macrocephaly and microcephaly, respectively.<sup><xref ref-type="bibr" rid="bib71">71</xref></sup> May be caused by <italic>MAPK3</italic> dosage effects</td></tr><tr><td align="left" valign="top" charoff="50">1q21.1 CNV</td><td align="left" valign="top" charoff="50">Reciprocal deletion and duplication CNV implicated in microcephaly and macrocephaly, respectively.<sup><xref ref-type="bibr" rid="bib72">72</xref></sup> May be caused by <italic>CHD1L</italic> and/or <italic>BCL9</italic> dosage effects</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: ASD, autism spectrum disorder; CNV, copy number variant; NDD, neurodevelopmental disorder; NSC, neural stem cell.</p></fn><fn id="t1-fn2"><p>Many genes on this list have several functions (for example, <italic>NRXN1, NLGN4X</italic> and <italic>SHANK3</italic> in cell adhesion), and here we have purposely shown only those functions associated with cell proliferation and differentiation, providing evidence that it is this pathway that unifies genes and loci associated with NDDs important to behavior and cognition. Our model predicts that genes that function to promote differentiation will show increased markers (microRNA, messenger RNA, DNA methylation patterns) of proliferation under disease conditions, whereas those genes that function to repress differentiation or allow NSCs to proliferate, will show increased markers of differentiation under disease conditions.</p></fn></table-wrap-foot></table-wrap></floats-group></article>